Stereochemical comparison of nebivolol with other β-blockers

Chirality

Volumn 20, Issue 2, 2008, Pages 103-109

  Siebert, Carsten D ^a,c   Hänsicke, André ^b   Nagel, Thomas ^b  

^a GOETHE UNIVERSITY   (Germany)

^b Berlin Chemie AG   (Germany)

^c NONE   (Germany)

Author keywords

blockers; Enantiomer; Eutomer; Hydroxypropanolamine structure; Racemate

Indexed keywords

ADRENALIN; ATPURE; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DISPATIM; ESATENOLOL; HYDROXYPROPANOLAMINE; LEVOBUNOLOL; NEBIVOLOL; NORADRENALIN; PENBUTOLOL; PROPANOLAMINE DERIVATIVE; TIMOLOL; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; CHIRALITY; DRUG STRUCTURE; ENANTIOMER; PRIORITY JOURNAL; RACEMIC MIXTURE; REVIEW; STRUCTURE ANALYSIS;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BENZOPYRANS; ETHANOLAMINES; LUNG; RECEPTORS, ADRENERGIC; STEREOISOMERISM;

EID: 38549149892     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20509     Document Type: Review

References (18)

1. Siebert CD. Spatial view and description of nebivolol. Pharmazie Unserer Zeit 2004;33:450-454.
2. Mehvar R, Brocks DR. Stereospecific pharmacokinetics and pharmacodynamics of β-adrenergic blockers in humans. J Pharm Pharm Sci 2001;4:185-200.
3. Stoschitzky K, Lindner W. Specific and nonspecific effects of β-receptor blockers: stereoselectively different properties exemplified by (R)- and (S)-propranolol. Wien Med Wochenschr 1990;140:156-162.
4. Siebert CD, Tampe N. Stereoisomers of compounds with symmetric constitutions. Arch Pharm (Weinheim) 2005;338:534-8.
5. Brittain RT, Drew GM, Levy GP. The α- and β-adrenoceptor blocking activities of labetalol and its individual stereoisomers in anaesthetized dogs and in isolated tissues. Br J Pharmacol 1982;77:105-114.
6. Riva E, Mennini T, Latini R. The α- and β-adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers. Br J Pharmacol 1991;104:823-828.
7. Brixius K, Bundkirchen A, Bolck B, Mehlhorn U, Schwinger RH. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol 2001;133:1330-1338.
8. Chandrasekhar S, Venkat Reddy M. Enantioselective total synthesis of the antihypertensive agent (S,R,R,R)-nebivolol. Tetrahedron 2000;56:6339-6344.
9. Van Lommen G, De Bruyn M, Schroven M. Synthesis and pharmacological properties of nebivolol, a new antihypertensive compound. J Pharm Belg 1990;45:355-360.
10. Zakharkin LI, Khorlina IM. Reduction of esters of carboxylic acids into aldehydes with diisobutylaluminum hydride. Tetrahedron Lett 1962;14:619-620.
11. Aboul-Enein HY, Ali I. HPLC enantiomeric resolution of nebivolol on normal and reversed amylose based chiral phases. Pharmazie 2001;56:214-216.
12. Tuchalski G, Emmerling F, Gröger K, Hänsicke A, Nagel T, Reck G. X-ray investigations of nebivolol and its isomers. J Mol Struct 2006;800:28-44.
13. Steinhilber D, Schubert-Zsilavecz M, Roth HJ. Medizinische Chemie -Targets und Arzneistoffe [Medicinal Chemistry - Targets and Drugs]. Germany: Deutscher Apotheker Verlag Stuttgart; 2005. p 209-216.
14. Pauwels PJ, Gommeren W, Van Lommen G, Janssen PA, Leysen JE. The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers. Mol Pharmacol 1988;34:843-851.
15. Johannes CW, Visser MS, Weatherhead GS, Hoveyda AH. Zr-catalyzed kinetic resolution of allylic ethers and mo-catalyzed chromene formation in synthesis. Enantioselective total synthesis of the antihypertensive agent (S,R,R,R)-nebivolol. J Am Chem Soc 1998;120:8340-8347.
16. Stoleru L, Wijns W, van Eyll C, Bouvy T, Van Nueten L, Pouleur H. Effects of D-nebivolol and L-nebivolol on left ventricular systolic and diastolic function: comparison with DL-nebivolol and atenolol. J Cardiovasc Pharmacol 1993;22:183-190.
17. Van Peer A, Snoeck E, Woestenborghs R, Van De Velde V, Mannens G, Meuldermans W, Heykants J. Clinical pharmacokinetics on nebivolol. A review. Drug Invest 1991;3 (Suppl 1):25-30.
18. Bakris GL. Pharmacological augmentation of endothelium-derived nitric oxide synthesis. J Manag Care Pharm 2007;13 (5 Suppl):S9-S12.